Explore the latest developments in influenza treatment through this 54-minute conference talk from ICAAC 2014, presented by the American Society for Microbiology. Delve into the analysis of phase 2 and phase 3 clinical trials for a groundbreaking single-dose neuraminidase inhibitor (NAI) called paramivir. Learn about its safety and efficacy in alleviating influenza symptoms, including fever reduction and decreased viral shedding, when administered within 48 hours of symptom onset. Gain insights from special guests Bill Sheridan of BioCryst and Rich Whitley from the University of Alabama at Birmingham as they discuss topics such as the rationale behind developing a new drug, optimal timing for physician visits, and the importance of flu immunization. Examine the differences between phase 2 and phase 3 trials, placebo-controlled studies, and FDA application processes. Discover key information about dosing, shelf life, and secondary endpoints. Compare data on Japanese and Caucasian patient responses, and engage with Twitter questions addressed during the presentation.
Overview
Syllabus
Introduction
Phase 2 vs Phase 3
When to use neuraminidase inhibitors
Why develop a new drug
When to go to your physician
Immunizing with Flu
Nursing Home Treatment
placebocontrolled study
FDA application
Phase 3 trial
Phase 2 trial
Secondary endpoints
Dose
Shelf Life
Doses Used
Data
Twitter Questions
Japanese vs Caucasians
Taught by
American Society for Microbiology
